The FDA has approved MTAV, a groundbreaking treatment for melanoma, a potentially deadly skin cancer. Known as tumor-infiltrating lymphocyte (TIL) therapy, this innovative approach uses a patient’s own immune cells harvested from the tumor, multiplied in a lab, and reintroduced to combat the cancer. In clinical trials, 30-40% of patients experienced tumor shrinkage or remission. While priced at $515,000 for a one-time procedure, researchers aim to expand its application to other cancers, offering hope for lasting remission and improved outcomes.